Archer Pharmaceuticals, Inc. (Archer) specializes in targeted drug discovery for Alzheimerâs disease. Clinical development of Nilvadipine as a therapeutic for Alzheimerâs Disease showed it to be well tolerated in Alzheimer's disease patients. With very string ties to University of Florida, other Archer compounds ready to enter clinical development are ARC029 and ARC031, both of which are targeted at the reduction of soluble amyloid proteins in the brain. In addition, Archer hasother agents in the preclinical stage, including Gamma Secretase Inhibitors and BACE Inhibitors. These are designed to attack the Alzheimerâs disease soluble amyloid in different ways, providing complementary approaches to the lead compounds. Archer also performs contract R & D and its Custom Synthesis Division provides services for drug discovery, process research, development and early clinical manufacturing of pharmaceutical drug substances. Archer laboratories have been designed specifically to produce bulk Active Pharmaceutical Ingredient suitable for use in preclinical toxicology, large clinical trials and finished prod
